Preserving fertility in young patients with endometrial cancer: current perspectives

被引:49
作者
Kalogera, Eleftheria [1 ]
Dowdy, Sean C. [1 ]
Bakkum-Gamez, Jamie N. [1 ]
机构
[1] Mayo Clin, Div Gynecol Surg, Rochester, MN USA
来源
INTERNATIONAL JOURNAL OF WOMENS HEALTH | 2014年 / 6卷
关键词
early stage endometrial cancer; fertility sparing; preserving fertility; conservative treatment; progestin; levonorgestrel intrauterine device;
D O I
10.2147/IJWH.S47232
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries and affects predominantly postmenopausal women. It is estimated, however, that 15%-25% of women will be diagnosed before menopause. As more women choose to defer childbearing until later in life, the feasibility and safety of fertility-sparing EC management have been increasingly studied. Definitive treatment of total hysterectomy and bilateral salpingo-oophorectomy precludes future fertility and may thus be undesirable by women who wish to maintain their reproductive potential. However, the consideration of conservative management carries the oncologic risks of unstaged EC and the risk of missing a synchronous ovarian cancer. It is further complicated by the lack of consensus regarding the initial assessment, treatment, and surveillance. Conservative treatment with progestins has been shown to be a feasible and safe fertility-sparing approach for women with low grade, early stage EC with no myometrial invasion. The two most commonly adopted regimens are medroxyprogesterone acetate at 500-600 mg daily and megestrol acetate at 160 mg daily for a minimum of 6-9 months, with initial response rates commonly reported between 60% and 80% and recurrence rates between 25% and 40%. Photodynamic therapy and hysteroscopic EC excision have recently been reported as alternative approaches to progestin therapy alone. However, limited efficacy and safety data exist. Live birth rates after progestin therapy have typically been reported around 30%; however, when focusing only on those who do pursue fertility after successful treatment, the live birth rates were found to be higher than 60%. Assisted reproductive technology has been associated with a higher live birth rate compared with spontaneous conception, most likely reflecting the presence of infertility at baseline. Close follow-up is of paramount importance, and definitive treatment after completion of childbearing is advised.
引用
收藏
页码:691 / 701
页数:11
相关论文
共 127 条
  • [1] Uterine cancer after use of clomiphene citrate to induce ovulation
    Althuis, MD
    Moghissi, KS
    Westhoff, CL
    Scoccia, B
    Lamb, EJ
    Lubin, JH
    Brinton, LA
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 161 (07) : 607 - 615
  • [2] Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma
    Azim, Amr
    Oktay, Kutluk
    [J]. FERTILITY AND STERILITY, 2007, 88 (03) : 657 - 664
  • [3] Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma: Review of the Literature and Presentation of a Series
    Bakkum-Gamez, Jamie N.
    Kalogera, Eleftheria
    Keeney, Gary L.
    Mariani, Andrea
    Podratz, Karl C.
    Dowdy, Sean C.
    [J]. JOURNAL OF GYNECOLOGIC SURGERY, 2012, 28 (04) : 262 - 269
  • [4] Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study
    Barakat, RR
    Bundy, BN
    Spirtos, NM
    Bell, J
    Mannel, RS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 587 - 592
  • [5] Bernardini L, 1996, HUM REPROD, V11, P2785
  • [6] Berstein L, 2002, EUR J OBSTET GYN R B, V105, P161
  • [7] Conservative treatment of early endometrial cancer
    Bovicelli, Alessandro
    D'Andrilli, Giuseppina
    Giordano, Antonio
    De Iaco, Pierandrea
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (06) : 1154 - 1158
  • [8] Progestin Intrauterine Device in an Adolescent With Grade 2 Endometrial Cancer
    Brown, Alaina J.
    Westin, Shannon N.
    Broaddus, Russell R.
    Schmeler, Kathleen
    [J]. OBSTETRICS AND GYNECOLOGY, 2012, 119 (02) : 423 - 426
  • [9] Progestogen treatment options for early endometrial cancer
    Cade, T. J.
    Quinn, M. A.
    Rome, R. M.
    Neesham, D.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2010, 117 (07) : 879 - 883
  • [10] Caserta D, 2014, PANMINERVA MED, V56, P85